BetterLife Pharma Inc. BETR
CNSX
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.73M | 1.31M | 1.24M | 1.39M | 1.63M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.85M | 1.38M | 1.30M | 1.43M | 1.67M |
| Operating Income | -1.85M | -1.38M | -1.30M | -1.43M | -1.67M |
| Income Before Tax | -2.52M | -1.39M | -1.09M | -1.36M | -581.60K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.52 | -1.39 | -1.09 | -1.36 | -0.58 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 16.20K | 18.30K | 12.70K | 34.00K | -4.10K |
| Net Income | -2.51M | -1.37M | -1.08M | -1.32M | -585.80K |
| EBIT | -1.85M | -1.38M | -1.30M | -1.43M | -1.67M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | -0.01 | -0.01 | -0.01 | 0.00 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 620.11M | 607.50M | 583.17M | 561.22M | 538.82M |
| Average Diluted Shares Outstanding | 620.11M | 607.50M | 583.17M | 561.22M | 556.11M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |